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Toxicology studies utilizing animals and in-vitro cellular or tissue preparations have been used to study the toxic effects and mechanism of action of drugs and chemicals and to determine the effective and safe dose of drugs in humans and the risk of toxicity from chemical exposures. Testing in animals could be improved if animal dosing using the mg/kg basis was abandoned and drugs and chemicals were administered to compare the effects of pharmacokinetically and toxicokinetically equivalent serum levels in the animal model and human. Since alert physicians or epidemiology studies, not animal studies have discovered most human teratogens and toxicities in children, animal studies play a minor role in discovering teratogens and agents that are deleterious to infants and children.  In vitro studies play even a less important role, although they are helpful in describing the cellular or tissue effects of the drugs or chemicals and their mechanism of action. One cannot determine the magnitude of human risks from in-vitro studies when they are the only source of toxicology data. Performing toxicology studies on adult animals is performed by pharmaceutical companies, chemical companies, the Food and Drug Administration (FDA), many laboratories at the National Institutes of Health and scientific investigators in laboratories throughout the world. While there is a vast amount of animal toxicology studies performed on pregnant animals and adult animals, there is a paucity of animal studies utilizing newborn, infant and juvenile animals. This deficiency is compounded by the fact that there are very few toxicology studies performed in children. That is one reason why pregnant women and children are referred to as “therapeutic orphans.” When animal studies are performed with newborn and developing animals, the results demonstrate that generalizations are less applicable and less predictable than the toxicology studies in pregnant animals. While many studies reveal that infants and developing animals may have difficulty in metabolizing drugs and are more vulnerable to the toxic effects of environmental chemicals, there are exceptions that indicate that infants and developing animals may be less vulnerable and more resilient to some drugs and chemicals. In other words, the generalization indicating that developing animals are always more sensitive (Table 1) to environmental toxicants is not valid. In order for animal toxicology studies to be useful, animal studies have to utilize modern concepts of pharmacokinetics and toxicokinetics, as well as “Mechanism of Action” (MOA) studies in order to determine whether animal data can be utilized for determining human risk. One example is the inability to determine carcinogenic risks in humans for some drugs and chemicals that produce tumors in rodents, When the oncogenesis is the result of peroxisome proliferation, a reaction that is of diminished importance in humans.





There is realistic concern about the impact of environmental influences such as drugs and chemicals on the health of human populations. First, exposure to environmental agents continues despite successes in reducing exposures to known toxicants such as lead, PCBs and tobacco smoke and drugs are continually being developed for human use.. Second, there has been controversial concerns about the etiology of autism and other neurodevelopmental problems, and hypotheses that environmental influences may play a role in the prevalence of these and other childhood and adult conditions such as asthma and obesity. Third, there are many other conditions that are directly or indirectly related to environmental influences and are preventable, such as injuries, untoward consequences of alcohol, suicide, drug addiction, and gun-related deaths. This chapter deals with a complicated and important issue. Can the magnitude and type of environmental risks to the infant, child and adolescent be determined from animal studies and how different are these risks when compared to adult risks for the same toxicants? In many instances environmental toxicants will exploit the vulnerabilities and sensitivities of developing organisms. In other instances, there will be no difference between the developing organism and the adult when exposed to toxicants, and in some instances the children and adolescents may even withstand the exposures with less insult (Table 1a). Not only is it difficult to predict whether a chemical or drug will have a different NOAEL in children and adults we have to contend with two other problems.
1.	Whether infants, children and adolescents are more vulnerable is irrelevant in one sense because even if the NOAEL is the same, the effect on developing organisms can be more severe, because developmental events that are not present in adults can be affected. 
2.	Secondly, there are many diseases that occur in infants, children and adolescents that either do not occur, or rarely occur in adults (Table 1b). Some of these diseases are due to environmental agents or drugs. Are there others?
The difficulty that we have at this time is that in many situations we do not have enough data and/or scholarly techniques to arrive at a conclusion about the relative sensitivity of the developing organism to some environmental agents. Rather than arrive at conclusions about environmental agents or exposures for which there are insufficient data, investigative approaches need to be initiated to obtain the necessary data concerning agents and exposures that have not been clarified. So it is important that we initiate and expand quality research in environmental toxicology.
While chemicals and drugs can be evaluated for their toxic potential by utilizing in vivo animal studies and in vitro systems, it should be recognized that these testing procedures are only one component in the process of evaluating the potential toxic risk of drugs and chemicals.  The evaluation of the toxicity of drugs and chemicals should include, when possible, data obtained from a number of investigative approaches (Brent, 1986). These should include: 1) Epidemiological studies (Brent, 1986; Bent, 1972), 2) Secular trend or ecological trend analyses, 3) Animal studies (Brent,1964; Brent, 1980; Brent, 1988; Christian and Brent, 2001; Brent, 2002), 4) Pharmacokinetic, toxicokinetic, pharmacodynamic and toxicodynamic studies, 5) Mechanism of action studies (MOA), 6) Basic science studies that pertain specifically to the agent, such as MOA studies, which include receptor affinity, cytotoxicity, genotoxicity, organ toxicity, neurotoxicity, etc. (Brent, 1986; Brent, 1980; Christian and Brent, 2001; Brent, 2001). Human studies are expensive and take years to complete. Therefore, scientists have asked whether appropriate animal models are available to evaluate the risks of environmental toxicants to the infant, child and adolescent. This is not an easy task.
There are a few toxicological principles that should precede the specific discussion. Frequently drugs or chemicals are grouped into categories, i.e. pesticides, trihalomethanes, organochlorines, solvents, progestins, heavy metals, chemotherapeutic agents, etc. It is important to note that this type of classification may be useful for some purposes, but not for concluding generalizations about the toxic effects of all the agents in the group. As an example, the FDA (1999) published a report in the Federal Register disclaiming the term progestins to describe a group of drugs with identical effects and toxicity. Secondly, chemicals may be referred to as “poisons.” This is not a useful label because every known chemical or drug has an exposure that is toxic as well exposures that have no effect. Paracelsus stated in the 16th century, “ What is there that is not poison? All things are poison and nothing is without poison. Solely, the dose determines that a thing is without poison.”
Three areas of animal testing will be discussed.
A.	Reproductive effects from exposures during embryonic and fetal development.
B.	Toxic effects of drugs and chemicals administered to animals after birth as newborns, infants, juvenile animals and adults.
C.	 Oncogenic effects of environmental toxicants

A.	Utilization of animal studies to determine reproductive risks in humans (teratogenesis, growth retardation, pregnancy loss, stillbirth and infertility).
Clinicians have little training on how to interpret animal toxicology studies during medical school and residency training. This is probably true of reproductive toxicology studies more than in any other area of animal testing. While this publication deals primarily with postnatal animal studies, the extensive animal studies dealing with environmental toxicant exposures performed during embryonic development exemplify important toxicology principles. Unfortunately, for physicians, the most frequent source of animal testing information is from the package insert or the PDR (2003). The PDR utilizes the FDA’s (Food and Drug Administration) classification of reproductive risks, partly based on animal testing. The categories are A, B, C, D and X. The A category includes drugs that have no risk for reproductive effects. The B, C and D categories have increasing risks and the X category includes drugs like methotrexate, Acutane or thalidomide that should not be used in pregnant women or women of reproductive age who are not on contraceptives. These categories are misleading more than they are helpful. Teratologists, obstetricians and other clinicians who counsel pregnant women have been very critical of the FDA classification (Brent, 1982) because the classification ignores the basic principles of teratology (Brent, 1999) and the importance of modern pharmacokinetics when evaluating animal studies (Brent, 1988). In 1990 an article was published which indicated that of the 200 most frequently prescribed drugs, none of them represented a significant teratogenic risk (Friedman, et al., 1990). Yet the FDA placed only, a small proportion of these drugs in category A. There are many reasons for these misclassifications, but the most important reason is the misapplication of animal testing results. Let me give you some examples.
When a new drug is marketed or a new environmental toxicant is discovered, frequently the only information that is available is the animal data. Three examples will be used to emphasize the difficulties that occur.
1.	Meclizine produces cleft palate at very high exposures in the rat
2.	Leflunomide and its method of action (MOA)
3.	Radiation produced mental retardation. Is mental retardation a deterministic or stochastic effect?
1. Meclizine is an antihistamine with a lengthy history and like most antihistamines has not been demonstrated to have reproductive toxicity in multiple epidemiological studies. Yet its pregnancy category classification is B, primarily because “Reproductive studies in rats have shown cleft palates at 25 to 50 times the human dose.” Actually, what the clinician needs to know is what is the blood level in the rat and mouse when teratogenesis is produced and how does that blood level compare with the level in patients receiving therapeutic doses of the medication. Without this information, the animal experiments are meaningless. There are hundreds of drugs in categories B and C with animal studies using the archaic mg/kg dose regimen. This same failing has occurred in toxicological studies with environmental toxicants (lead, mercury, PCBs, pesticides, fungicides); namely, utilizing mg/kg exposures in rodents or other animals rather than determining serum levels in the animal and the human population for which there was concern. Fortunately, more recent environmental toxicology studies have been using modern toxicokinetic techniques, but serum levels of these toxicants are not always available in humans.
2. Leflunomide (Brent, 2001) is a new drug (1998) used to treat rheumatoid arthritis. It has a box warning for reproductive effects (teratogenesis) and has been placed in category X.  Since there were no human data available at the time of marketing, the label was based on the animal studies and stated, 
“There are no adequate and well-controlled studies evaluating Arava™ (leflunomide) in pregnant women. However, based on animal studies, leflunomide may cause fetal death or teratogenic effects when administered to a pregnant woman.”
Leflunomide is a novel isoxazole immunomodulatory agent that inhibits de novo pyrimidine synthesis and has antiproliferative activity. In vitro, after mitogen stimulation, the active metabolite of leflunomide inhibits T cell proliferation, DNA synthesis, and the expression of certain cell surface and nuclear antigens directly involved in T cell activation and proliferation. It inhibits mitogen-stimulated proliferation of human peripheral blood mononuclear cells (PBMCs) and proliferation in transformed murine and human cell lines, in a dose-dependent fashion. It has been demonstrated that the active metabolite binds to, and is a potent inhibitor of dihydroorotate-dehydrogenase (DHO-DH), an enzyme in the de novo pyrimidine synthesis pathway important for DNA synthesis. Together, these data suggest that at serum concentrations that are achievable in patients, leflunomide inhibits de novo pyrimidine synthesis in activated lymphocytes and other rapidly dividing cell populations, resulting in reversible cell cycle arrest.
In embryotoxicity and teratogenicity studies in rats and in rabbits, leflunomide was embryotoxic (growth retarded, embryolethal, and teratogenic) in rats, consisting of malformations of the head, rump, vertebral column, ribs and limbs; and in rabbits, malformation of the head and bilateral dysplasia of the spine of the scapula. The no-effect level for embryotoxicity and teratogenicity in rats and rabbits was 1 mg/kg body weight, which resulted in serum levels of 3.7 and 4.1 g/ml, respectively.
The active metabolite of leflunomide, which is the pyrimidine antagonist, is maintained at a blood level of 40 g/ml in patients being treated. The decision to label leflunomide as having a teratogenic risk was based on the fact that the human serum level was in the range of the teratogenic blood level in the animal models. So the initial labeling was an appropriate precaution to prevent birth defects.
After four years of treatment of rheumatoid arthritic patients and no indication of an increase in teratogenesis in a very small group of pregnant patients who were treated and continued their pregnancy to term, we can reanalyze the animal data as follows. This is referred to as the mechanism of action approach (MOA). The potential mechanisms of teratogenicity for leflunomide are:
1.	Suppression of DNA synthesis by interfering with pyrimidine synthesis based on the presumption that suppression is equal in the rat, rabbit and human at the same serum levels of the active metabolite of leflunomide. This was the basis of the X category labeling.
2.	The susceptibility of the enzyme to the active leflunomide metabolite that is involved in pyrimidine incorporation into DNA in the human and animal models.
3. The ability of the active metabolite of leflunomide to interfere with cell proliferation in the human and animal models.
If all three mechanisms of action were operative to the same degree at the same serum level in the animals and the patients, then there would be concurrence and the human risks would be determined to be identical from studying all three mechanisms. In-vitro studies of the active metabolite of leflunomide, revealed that the rat was 40 times more sensitive to the suppression of dihydroorotate-dehydrogenase (DHO-DH) than the human and that the rat was 328 times more sensitive to the active metabolite of leflunomide than was the human in suppressing cell proliferation. 
What this means is that if enzyme suppression or antiproliferative activity is the mechanism (MOA) of teratogenicity in the rat, then the clinical use of leflunomide in pregnant women would probably not be teratogenic. But no one would act on these findings without confirmation from the ongoing epidemiologic surveillance of this drug. However, this is an example where modern pharmacokinetic studies have improved risk assessment and made epidemiological studies understandable.
	3. In utero Effects of Ionizing Radiation on the Risk of Mental Retardation
Here is an example where animal behavioral studies and concomitant pathology were helpful in resolving an important issue with regard to in-utero radiation induced mental retardation. The main issue with regard to the risk of mental retardation following an in-utero exposure to ionizing radiation pertains to whether the risk from exposure is stochastic (no threshold) or deterministic (threshold effect) (Table 3). The possibility that 0.01 Sv (1 rad) might double the risk of mental retardation was suggested in 1984 (Otake and Schull, 1984).
From the perspective of biological plausibility and the results of animal studies, it would appear that the data favor the viewpoint that mental retardation is a deterministic effect with a threshold above 0.2 Sv (Brent, 1999; Jensh, et al., 1986; Jensh, et al., 1987; Jensh and Brent, 1986; Jensh and Brent, 1987; Brent, et al., 1987; Jensh and Brent, 1988; Brent, et al., 1986; Miller, 1999). Histological examination of the irradiated brain exposed to 0.01 Sv reveals no pathological consequences that could account for severe mental retardation (Jensh, et al., 1995). That would mean that the pattern of effects produced by ionizing radiation that accounts for mental retardation when the fetus is exposed to 0.5 to 2 Sv. does not occur at very low exposures. Furthermore, additional studies by Schull and Otake (1999) revealed that these authors were able to quantify the risk of reduced intellect following in utero ionizing radiation exposures. They estimated that there was a reduction in intellect of approximately 30 IQ points per Sv. in their studies. Even if there was a linear relationship between the dose and IQ reduction, one could predict that .01 Sv could not account for a doubling of the incidence of mental retardation, since a linear extrapolation of Otake and Schull’s data would only represent a maximum reduction of 0.3 of an IQ point at .01 Gy.  Behavioral studies in animals were unable to demonstrate neurobehavioral effects below .02 Gy (Jensh, et al., 1986; Jensh, et al., 1987; Jensh and Brent, 1986) (Table 3). While one has to be careful in extrapolating animal data to humans, the lack of neurobehavioral effects from in utero irradiation supports the other findings that indicate that mental retardation is a threshold (deterministic) effect (Table 2).
Once a drug, chemical or other agent is suspected of producing congenital malformations or other reproductive effects in humans, appropriate use of in vitro and in vivo testing can be helpful in evaluating the specific allegation and in determining the mechanism of action of the agent. Whole animal testing, while serving important and useful purposes, can still be improved so that they can be better utilized to estimate human reproductive risks. These improvements are listed in Table 4.
In vitro tests can be utilized to study the mechanisms of teratogenesis and embryogenesis, and for preliminary screening procedures. But in vitro studies will never be able to be predictive of human teratogenic risks at particular exposures without the benefit of data obtained from whole animal mammalian studies (Tables 4, 5, 6) and epidemiological studies (Brent, 1988; Brent, 2002; Brent, 1986; Schardein, 2000). In spite of the advances pertaining to in vitro and in vivo testing for teratogenicity, human epidemiological surveillance by various methodologies is, and will be, our most powerful tool for discovering human reproductive toxins and teratogens. It may be difficult for experimental teratologists to accept the fact that alert physicians and scientists have been the most prominent contributors to the discovery of the environmental causes of birth defects (Brent, 1972) (Table 5).
B.	The effects of environmental toxicants that are administered to animals after birth as newborns, infants, juvenile animals and adults for determining human risks.
It is obvious that animal experiments cannot be planned to consider all the variable effects that occur in the human. And in fact, there are situations in animal studies that differentiate the animal species from the human. For example, coprophagy and other behaviors in rodents and other species can markedly alter the dynamics of toxicity studies. Differences in absorption, metabolism and excretion of drugs and chemicals represent the greatest barrier to applying risks obtained from animal studies directly to the human. 
It is hoped that regulatory agencies and toxicologists who deal with issues of developmental toxicity will develop animal models that will predict toxicological effects in children and adolescents from exposure to drugs and chemicals. While this is an optimistic view, Done (1964) pointed out, that although the number of drug hazards that have proven to be unique in the infant has proven to be small, “Without exception, recognition of the proved hazard has come about only after widespread use, and then usually when tragic consequences focused attention on the drug.” (Done, 1964).
Animal Toxicology studies
Historically the administration of drugs and chemicals to humans and animals in experimental studies utilizes the mg/kg exposure methodology. Even in the 1800s, there was recognition that there was not a proportional relationship between body weight and dose between the infant and the adult human (Hufeland,1830). It was apparent that appropriate infant doses of medication would in some cases be toxic in the adult and appropriate adult doses would be inadequate for the infant if the mg/kg approach were utilized. Animal investigators have long been aware of this dilemma. It became apparent that comparisons of toxicity or therapeutic effects bore a closer relationship to the 0.7 power of body weight and this figure was closely related to surface area (Dreyer and Walker, 1914; Behnke, 1956). Many physiological functions are proportional to surface area because the extracellular volume in humans is constant on a surface area basis. Therefore, the serum concentrations obtained from administration or exposure to drugs and chemicals on a surface area basis would result in serum concentrations that would be similar. This is more closely related to the 0.73 power of the weight at all ages in humans (Friis-Hansen, 1957; Friis-Hansen, 1961). If, on the other hand, drugs or chemicals are distributed in the total body water, then neither, the mg/kg or the surface area model will be accurate, since total body water is not a constant using the surface area constant or the mg/kg relationship. It is obvious that no one method of dose calculation for the young will be satisfactory for evaluating appropriate therapeutic doses or for determining toxic risks. If that is the case for human exposures, then animal toxicology studies based on the mg/kg or surface area basis will not be universally appropriate for determining human risks or proper doses (Table 1). In fact, the fields of pharmacokinetics and toxicokinetics have demonstrated that animal toxicology experiments have to be performed knowing the serum level of the drug or chemical in the human and utilizing those levels as a reference point for performing and reporting animal toxicology studies.
We are interested in the usefulness of information obtained from animal toxicology studies, utilizing drugs and chemicals for determining the risks to children and adolescents from these exposures. The largest literature in this field pertains to animal toxicology studies using newborn and infant animal models. Most of these studies are acute toxicology studies that utilize the mg/kg method of dosing the adult and infant animals. Much of the information is simply the determination of the lethal exposure or the effect on growth. The most important finding in these studies is that newborn and infant animals are not always more sensitive or more deleteriously affected by drugs and chemicals when compared to adults (Table 1).
Urethane, an anesthetic that is no longer used for that purpose, was unable to anesthetize newborn animals at exposures that anesthetized adults, while ether altered reflexes at lower concentration in newborn animals than in adults (Weatherall, 1960). Newborn mice and other animal species have demonstrated a tolerance to hypoxic conditions that is not present in adult animals (Cameron, 1941; Cassin and Herron, 1961; Fazekas, et al., 1941; Reiss and Haurowitz, 1929; Stafford and Weatherall, 1962). Newborn mice continued to breathe for a longer period when exposed to ether than adult mice (Barrow, 1933). Newborn mice had a prolonged survival when compared to adults that were exposed to asphyxia as a result of exposure to CO, HCN, CO2, H2 and CH3. Longer exposures to strychnine, curare, CN injection, strangulation, hypoxia or nitrobenzol were necessary to produce respiratory arrest in newborn mice as compared to adult mice (Reiss and Haurowtiz, 1929).
In summarizing the previously cited information, Done (1964) was cautious, pointing out the multiplicity and variability of experimental details in these studies. He concluded, 
“Some tentative generalizations and observations may be worth making. ---First, it is apparent that immaturity does not necessarily entail greater sensitivity. ---A notable example is thiourea, which is 50 to 400 times as toxic in the adult as in infant rats” (Mackenzie and Mackenzie, 1943).
On the other hand the animal experiments with chloramphenicol clearly demonstrated that this drug was more toxic in the infant rat than in the adult. Animal toxicity studies corroborated the toxicity reported in infants (Kent, et al., 1960; Michael, et al.,1960; Raynsford, 1963). 
In Done’s (1964) review of developmental toxicology he indicated that the newborn or infant animal was more sensitive to many drugs (Cloramphenicol, morphine, some other opiates, picrotoxin, tetracycline, novobiocin, some organophosphate anticholinesterases, atropine, histamine, sodium salicylate and less sensitive to others (ethanol, strychnine, metrazol, codeine, acetocycloheximide, thiourea, thyroid hormone). Many other drugs had sensitivities that were similar in the neonate and adult animal. But, of course, most of this data was based on the mg/kg dosage and the endpoints were simplistic, i.e. death or cessation of respiration.
Development Toxicity Studies in Juvenile Animal Models: Relevance for estimating developmental risks in humans.
Can concerns about developmental problems from exposure to developmental toxicants in children and adolescent be evaluated with appropriately designed animal studies? Selevan et al. (2000) indicate “that little concrete information exists on critical windows for exposure during the postnatal period (Hunt, et al., 1982; Kimmel, et al., 1992). However, a systematic examination of available data on critical windows of vulnerability during postnatal development has not been performed. Most available data are focused on prenatal exposures. In 1954, Otis and Brent compared the stages of embryonic and fetal development of the mouse and human in great detail. As intrauterine development proceeded the congruence of developmental stages diverged. We know today that the development of the brain in the human fetus in the latter part of gestation is congruent with postnatal brain development in the mouse. There has been no similar projects to correlate stages of human development and their most vulnerable stages in postnatal animal models. Postnatal exposures have been examined for only a few agents (e.g., lead, pesticides, radiation) (Daniels, et al., 1997; Needleman, et al., 1990; Miller, 1995; Wadsworth and Kuh, 1997). And it can be stated that the pesticide analysis is far from definitive for the following reasons. First, the term pesticide includes a wide array of chemicals (insecticides, nematocides, rodenticides, herbicides, defoliants, and fungicides). Secondly, while some of these agents may have a lower LD/50s for developing organism, that does not necessarily mean that the NOAEL or threshold exposure is different for adult and developing organisms The most important aspects in designing these animal studies is the application of modern toxicokinetics and pharmacokinetics. Exposure levels should include exposures that occur in the environment and a major effort should be made to determine the no-adverse-effect level (NOAEL) and threshold exposure.
The developmental events that can be affected by environmental exposures to drugs, chemicals and physical agents include the following developmental events that occur during childhood and adolescent development.
1.	Interference with growth, epiphyseal development and epiphyseal closure: Alterations in growth from exposure to environmental toxicants can result in accelerated growth or growth retardation. Accelerated growth and maturation can result in larger stature or smaller stature. Smaller stature can result from the combination of growth acceleration and earlier epiphyseal closure. Drugs and chemicals that are cytotoxic or interfere with normal hormonal and endocrine relationships have the potential for altering growth and development. But the exposure has to be above the threshold for producing results. Useful information concerning the effect of environmental toxicants can be obtained by exposing animals during various windows of development before puberty. 
2.	Reproductive and hormonal effects: Do exposures during childhood and adolescence to drugs and chemical environmental agents possessing hormonal activity, cytotoxicity or other effects, alter the timing of puberty, the maturation of sexual organs including breast development, affect fertility or the normalcy of spermatogenesis and oogenesis (Pryor, et al., 2000)?  Gamete production and availability in both the male and female is initiated at puberty, spermatogenesis in the male and ovulation in the female. Immature and pubertal rats appear to be more sensitive than adults to testicular toxicity induced by phthalate esters (Gray and Gangolii, 1986; Sjorberg, et al., 1986; Dostal, et al., 1988), but the primate does not have the same susceptibility as the rat. The pesticide, 1,2-dibromo-3chloropropane (DBCP) affects the immature rats testes more severely than the adult, although the testes of the adult is also affected, since DBCP was banned because occupational exposure in adult males resulted in infertility (Lui and Wysocki, 1987; Warren, et al., 1988). Lemasters et al. (2000) pointed out that immature animals are not always more sensitive than adults. Fetal Leydig cells are less sensitive than adult Leydig cells to ethane dimethane sulfonate, a known Leydig cell toxicant (Kelce, et al. 1991). Before the onset of puberty, rats are insensitive to testicular toxicity following exposure to 1,3-dinitrobenzene, a Sertoli cell toxicant, and young adults are less sensitive than mature adult males (Brown, et al., 1994). While spermatogenesis has many similarities among mammalian species, oogenesis varies considerably. Even the number of primordial ova varies in different mammalian species (Pryor, et al., 2000). Female rats exposed to 4-vinylcyclohexene diepoxide (VCD) results in destruction of oocytes in small follicles and adult rats are less sensitive to the ovatoxicity of this compound (Flaws, et al., 1994). Will the onset of menopause be affected by certain chemical and drug exposures during childhood and adolescence? 
Environmental toxicants can affect thyroid development and therefore have a direct impact on neurological normalcy, since normal thyroid function is crucial for normal CNS development (Brouwer, et al., 1995). The most common environmental cause of mental retardation in the world is endemic cretinism due to iodine deficiency. Therefore, it is not an environmental toxicity in the usual sense (Morreale de Escobar, et al., 1997; Donati, et al., 1992). On the other hand, children’s thyroids have been demonstrated to be more sensitive to the oncogenic effect of external ionizing radiation exposure as well as radioactive iodine localization in the thyroid (Miller, 1974; Miller 1996; Preston, et al., 2002; Pierce, et al., 1996).
With regard to environmental toxicity, questions have been raised about the effect of organochlorine compounds (PCBs, dioxins) on thyroid function (McKinney and Waller, 1994; Maier, et al., 1994; McKinney, et al., 1985; Ness, et al., 1993; Koopman-Esseboom, et al., 1994; Morse, et al., 1996). It is difficult to determine the magnitude of the risk of these compounds on thyroid function with the data that is available. The worldwide problem of endemic cretinism from iodine deficiency is without question a real problem.  There are few studies, which evaluate the risk of environmental toxicants on thyroid function or other endocrine organs when exposed during childhood and adolescence.
In the article by Pryor et al. (2000) dealing with reproductive effects, the authors state, “Although it is the dose that makes the poison, there is no doubt that timing of the exposure may be as important as dose in determining the potential toxicity of a compound to the reproductive system.” This is not a rare statement in the “environmental literature,” but it is not correct. Timing of exposure is important, but it is not important if the actual exposure is below the threshold. If the threshold dose for an effect at any stage of development is not exceeded, timing is irrelevant.
3.	Do exposures to environmental agents during childhood and adolescence affect the normalcy of the adult immune system? While it is true that many chemicals can affect the immune system at high exposures, the question of whether environmental exposures play any role in altering the immune system has not been answered. It has not even been determined whether this is a high priority area to be studied using appropriate animal models. In the review on this subject by Holladay and Smialowicz (2000) the authors state, “the possibility that developmental exposure to immunotoxicants may play a role in inducing or exacerbating hypersensitivity or autoimmune responses needs to be investigated in laboratory animals.”
4.	Vulnerability of the nervous system to environmental agents during childhood and adolescence. Critical developmental processes during the development of the central nervous system include: 1) the development of the germ layers, 2) neurulation, 3) the closure of the neural tube, 4) neuronal proliferation, 5) neuronal migration, 6) differentiation, 7) synaptogeneisis, 8) myelination, and 9) apoptosis. These processes can be studied in animal models (Rodier and Reynolds, 1977; Rodier, 1980). The first five or six developmental events have occurred in the fetus, before the postnatal period of central nervous system development during childhood and adolescence. Rice and Barone (2000) raise the question as to whether schizophrenia, dyslexia, epilepsy and autism may be caused by environmental influences. Weiss and Landrigan (2000) speculate that ADHD and Parkinsons’s disease may be due to exposures that occurred during development. We know that epilepsy can be caused by trauma, infection and genetic abnormalities and that autism can be produced by an insult to the nervous system very early in embryonic development (Stromland, et al., 1994; Rodier, et al., 1996). Rice and Barone (200) also raise the question as to whether early exposures to toxicants can cause acceleration of age-related decline in central nervous function. Some of these questions are amenable to animal studies in both rodents and primates. But these studies are neither easy to perform or inexpensive, especially in the primate. Two important problems exist with regard to evaluating the risk of neurotoxicity of environmental toxicants at various stages of development utilizing animal models.
1. Information that equates various stages of prepartum and postpartum brain development in human and animal models is not, as yet, precisely defined (Otis and Brent, 1954).
2. We cannot be certain of our ability to identify and recognize the most important neurological diseases in animal models, i.e. ADHD, dyslexia, autism, schizophrenia, Parkinsons’s disease, etc. 
In the publication by Adams et al. (2000), a number of important concepts are discussed.  The authors indicate, “Inherent in the brain’s protracted period of development, -- is also the phenomenon of neuroplasticity, and the nervous system’s consequent potential for compensation after insult.” This is probably the most difficult area to investigate in both the human and in animal models. In fact, it is such a difficult area, that the authors indicated that it was beyond the scope of their review. But it is an area that could be investigated utilizing animal models. Adams et al. (2000) specifically discussed the topic of the “Vulnerability during the adolescent period of development.” They indicate that the brain of the adolescent undergoes “striking.” transformations, which is observed in many mammalian species. These regions include areas of remodeling of the prefrontal cortex and other forebrain regions that receive projections of the mesolimbic dopaminergic terminal projections. In addition, there is a decline in the volume of the prefrontal cortex in humans (Jernigan, et al., 1991) and the rat (Van Eden, et al. 1999). According to Adams et al. (2000) there is also substantial synapse elimination of presumed glutaminergic excitatory input to the motor cortex (Zecevic and Rakic, 1991) while dopaminergic input to the prefrontal cortex increases during adolescence to reach levels higher than that seen earlier or later in life (Lewis, 1997). Estimates of basal synthesis and turnover of dopamine decline in the prefrontal cortex during adolescence in rats, that contrasts with the increase in these measures reported in the nucleus accumbens and striatal dopamine terminal region of adolescent rats (Anderson, et al., 1997; Teicher, et al., 1993). Maturational events have also been reported in a variety of other areas including the hippocampus in humans (Benes, 1989), rodents (Dumas and Foster, 1998) and in the hypothalamus (Choi, et al., 1997).” Adams et al. (2000) suggest that the adolescent brain may be especially vulnerable during this period of remodeling and refers to the publications of Salimov et al. (1996) who reported the toxic influence of alcohol exposure during this stage of development in the rat. All these studies are of interest and inform the reader about the developmental processes that may be occurring in the brain of adolescents. But few of these studies reveal whether environmental toxicants have any effects on these developmental processes.

C.	The utilization of animal studies to determine the oncogenic risks of environmental toxicants.
There is a truism in medicine that indicates that children are at greater risk for the induction of cancer than adults from exposure to agents which are mutagenic or have demonstrated oncogenic potential (Miller, 1996; Preston, et al., 2002; Pierce, et al., 1996;Zahm and Devesa, 1995). That is certainly proven for high doses of ionizing radiation, and for exposures to radioactive (Miller, 1995; Miller, 1974; Miller, 1996; Preston, et al., 2002; Pierce, et al., 1996). Studies of the oncogenic effects of radiation in Hiroshima and Nagasaki demonstrated that children have a higher risk of cancer following whole body irradiation. However, the higher proportion of acute lymphocytic leukemia in children and the increased risk of this disease in radiated children magnify this overall increased risk. The calculated overall risk of cancer in irradiated children has 95% confidence limits of 1.0 to 1.8 (Preston, et al., 2002; Pierce, et al., 1996).There are very few cancer studies in animals that expose the animals during a narrow window of time that would be equivalent to childhood or adolescence. Most animal cancer studies utilizing environmental chemicals and drugs involve life-long exposures. The children who were exposed to high doses of ionizing radiation in Hiroshima and Nagasaki did have an increased incidence of leukemia to a greater extent than did the exposed adults (Miller, 1996; Preston, et al., 2002; Pierce, et al., 1996). There are studies involving children and adolescents who have been treated for cancer with chemotherapeutic drugs and radiation and these survivors are at an increased risk of second cancers. However, when they become parents, they do not have offspring with an increased incidence of genetic diseases (Byrne, 1999, Winther et al. 2004, Boice et al. 2003). Animal studies that would only involve short exposures to proven human carcinogens during the stages that are equivalent for childhood or adolescence could be performed. The most appropriate first approach would be to select agents that have been demonstrated to be positive in a life-long animal study or agents that are definitely mutagenic as a first approach to determine the oncogenic sensitivity to environmental toxicants during various postnatal developmental stages.
There are extensive reports concerning the oncogenic effect of drugs and chemicals in life-long animal studies. Many of these cancer studies have evaluated environmental chemicals, i.e., organochlorine chemicals, ethylene oxide, pesticides, organic solvents, phthalates, acrylonitriles , trihalomethanes, etc. Most of these cancer studies have utilized rodents and have also exposed the animals at relatively high exposures. 
Many agents that have been demonstrated to be carcinogenic in humans will produce cancer in some laboratory animals, but not all laboratory animals. But all agents that have been demonstrated to be carcinogenic in animals are not carcinogenic in humans (Dybing and Sanner, 1999; Grisham, 1997; Hengstler, et al., 1999). When the mechanism of action (MOA) of a carcinogenic agent is understood, the relevance of the animal studies can be placed into proper perspective. 
The following two examples are animal studies that indicated a carcinogenic potential, but when the MOA was understood, these agents were determined not to have human carcinogenic potential at the levels of human exposure.
Animal studies have revealed marked differences among species with regard to the oncogenic susceptibility to environmental chemicals and drugs as exemplified by the phthalates (Astill, 1989; Elcombe and Mitchell, 1986; Goll, et al., 1999; Hasmall, et al., 1999; Hasmall, et al, 2000; Huber, et al., 1996; Kedderis and Batra, 1993; Kurata, et al., 1998; Woodyatt, et al., 1999). For example, chemicals, such as the phthalate DEHP, induce peroxisome proliferation in the rodent resulting in hepatocarcinogenicity, but there is less responsiveness in primates or human liver cells (Ashby, et al., 1994; Conway, et al., 1989; David, et al., 1999; Kluwe, 1981; Kluwe, 1982; Lawrence, et al., 2001; Marsman, et al., 1988; Mukherjee, et al., 1994; Palmer, et al., 1998; Schmid and Schlatte, 1985; Short, et al., 1987). There is much discussion and controversy in the literature regarding the mechanism of this carcinogenic effect; namely, the role of increased cell division as the cause of mutation and eventual carcinogenicity (Ames and Gold, 1990; Cohen, 1995; Farber, 1996; Melnick, et al., 1998; Preston-Martin, et al., 1990; Smith-Oliver and Butterworth, 1987). Whether the carcinogenicity is the result of mutation or some other mechanism related to peroxisome proliferation is of interest. But the important aspect of this topic is the marked difference in oncogenic susceptibility in various species (Elcombe and Mitchell, 1986; Kurata, et al., 1998; Lawrence, et al., 2001; Lambe, et al., 1999). Animal carcinogenicity studies utilizing the phthalates and other chemicals that stimulate the peroxisome proliferation response may not be appropriate models to determine human cancer risks.
The second agent that received much attention is saccharin, which produced bladder cancer when high doses of saccharin were administered to rodents. At high doses, precipitates of saccharin develop in the rodent bladder producing inflammation and proliferation that ultimately results in bladder tumors (Cohen, 1998; Cohen, 1999). Other experiments indicated that human exposures of saccharin would never result in the situation that occurred in the rodent.
The phthalate and saccharin experiences indicate that when the MOA for carcinogenesis is a threshold effect, that the risk may not be present at lower exposures and that species differences in metabolism and response may make it difficult to utilize animal risks to determine human risks. On the other hand when the oncogenic effect is related to a mutagenic agent, then the theoretical risk for a no-threshold or stochastic effect exists (Table 2, Figure 1).
In order to determine whether the oncogenic risk for drugs and chemicals is greater during postpartum animal development, protocols would have to be developed during these stages of animal development. Before embarking on the initiation of such testing, it would be important to determine if these studies would be of benefit for human assessment of oncogenic risks. Pilot studies could be performed utilizing known mutagenic or carcinogenic agents. The increased costs and possible benefits of the new information would have to be evaluated in order to determine whether we should initiate these developmental oncogenic studies. This is a difficult issue to settle. It might be better to perform research on MOA of carcinogenic agents and use that information in combination with the established animal carcinogenicity studies.

Conclusion
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Stochastic and threshold (deterministic) dose-response relationships of diseases produced by environmental agents

Phenomenon	Pathology	Site	Diseases	Risk	Definition
Stochastic 	Damage to a single cell may result in disease	DNA	Cancer, germ cell mutation	Some risk exists at all dosages; at low doses, risk is less than spontaneous risk	The incidence of the disease increases but the severity and nature of the disease remain the same
ThresholdDeterministic	Multicell-ular injury	Multiple, variable etiology, affecting many cell and organ processes	Malformation, growth retardation, death, toxicity, etc.	No increased risk below the threshold dose	Both the severity and incidence of the disease increase with dose






The effect of in utero ionizing radiation on developmental and neurological parameters in the rat.

Embryonic or fetal age	9th day	16th day
Dose of X-ray (Gy)	0.1	0.2	0.4	0.6	0.1	0.2	0.4	0.6
Effect								












Table 4. A whole animal teratology-reproductive toxicity protocol should include the following parameters and goals
_______________________________________________________________________
1.  Determine the reproductive effects at stages of gestation that may have markedly different endpoints; namely, pre-implantation, organogenesis, early fetal and late fetal stages.

2.  The importance of various reproductive endpoints may very considerably by the gestational stages being evaluated and exposures at one stage may exaggerate, modify or eliminate effects another stage:  i.e.,
a.  Teratogenesis
b.  Embryolethality
c.  Growth retardation
d.  Postnatal physiological, biochemical, developmental and behavioral effects.

3.  Determine the no-effect dose for the parameters mentioned in item 2 at various stages of gestation.

4.  Determine the ratio of the no-effect dose to the human therapeutic dose, usual exposure dose or maximal permissible exposure for the parameters mentioned in item number two (2).

5.	Determine the quantitative relationship between the human and animal model pharmacokinetics and toxicokinetics concerning the dose and the blood levels and the metabolism in the animal model and human.

6.	Determine the mechanism of action (MOA) of the environmental toxicant.






Table 5. How some human teratogens have been discovered.

Agent or drug	Major means of discovery.  How was the discovery made?




Trimethadione 1970Valproic acid 1982	+++	++		














Table 6. Protocol for environmental toxicant studies utilizing animals during developmental stages (neonatal, infancy and juvenile animals).

1.	The toxicant exposure should occur by the same route in the animal as it occurs in the human.
2.	Exposure should include a wide range and include the exposure level to which humans are exposed. 
3,	Serum or tissue concentrations of the toxicant or its active metabolite should be determined in humans in order to determine whether the human is being exposed to concentrations that deleteriously affect the animal model.
4.	Metabolism, half-life, turnover, mechanism of detoxification, mechanism of action (MOA) and excretion should be determined.
5, 	Biomarkers for evaluating the effects of toxicants in developing organisms should include, growth, maturation, time of puberty, neurobehavioral effects, fertility, specific organ and tissue toxicity and pathology at windows during various stages of development.
6.	The no-effect or threshold exposure should be determined for all toxic or detrimental findings.




Legend for Figure 1.
The dose response curve of environmental toxicants (drugs, chemicals and physical agents) can have deterministic (threshold) and/or stochastic effects.  Mutagenic and carcinogenic events are stochastic phenomena and theoretically do not have a threshold exposure below, which no risk exists.  At low exposures the risk still exists, but is usually below the spontaneous risk of cancer and mutations.    Whether the curve is linear or curvilinear for stochastic phenomena can be debated, but from a theoretical point, it traverses zero.  Toxicological phenomenon, such as teratogenesis and toxicology studies that do not involve mutagenic and carcinogenic effects, usually follow am S-shaped curve, with a threshold, below which no effects are expected.
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